Comparison of Botulinum Toxin Injections and Type 2 Thyroplasty for Adductor Spasmodic Dysphonia
The Laryngoscope · 2023
DOI: 10.1002/lary.30806 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2023. Verfasst von Tetsuji Sanuki und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head & Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Dysphonia, Laryngoplasty, Botulinum Toxins, Type A. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Practical Research Project for Rare/Intractable Diseases.
Abstract (Originalsprache)
Objectives
Injection of botulinum toxin type A (BTX) into intrinsic laryngeal muscles is the current gold standard therapy for adductor spasmodic dysphonia (AdSD). However, a surgical procedure could potentially offer more stable and long‐lasting voice quality to AdSD patients. Here, we report the long‐term results of type 2 thyroplasty (TP2) with TITANBRIDGE® (Nobelpharma, Tokyo, Japan) compared with those of BTX injections.
Methods
In total, 73 AdSD patients visited our hospital between August 2018 and February 2022. Patients were provided the option of BTX injections or TP2. They were assessed via the Voice Handicap Index (VHI)‐10 before treatments and at scheduled clinical follow‐ups at 2, 4, 8, and 12 weeks for BTX and at 4, 12, 26, and 52 weeks for TP2.
Results
Overall, 52 patients selected the BTX injection and had a pre‐injection mean VHI‐10 score of 27.3 ± 8.8. Following injections, the scores significantly improved to 21.0 ± 11.1, 18.6 ± 11.5, and 19.4 ± 11.7 at 2, 4, and 8 weeks, respectively. There were no significant differences between the pre‐injection scores and the 12‐week scores (21.5 ± 10.7). Alternately, 32 patients opted to be treated with TP2 and had a pre‐treatment mean VHI‐10 score of 27.7. All patients reported an improvement in their symptoms. Additionally, the mean VHI‐10 score significantly improved to 9.9 ± 7.4 at 52 weeks following treatment. There was a significant difference between the two treatment groups at 12 weeks. Some patients received both treatments.
Conclusion
These preliminary results provide important insights into the value of TP2 as a potential permanent treatment for AdSD patients. Level of Evidence 3 Laryngoscope , 133:3443–3448, 2023
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head & Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
ORCID-Profile: Tetsuji Sanuki
Förderung
- Japan Agency for Medical Research and Development
- Practical Research Project for Rare/Intractable Diseases
Zitieren
APA
Sanuki, T., & Takemoto, N. (2023). Comparison of Botulinum Toxin Injections and Type 2 Thyroplasty for Adductor Spasmodic Dysphonia. The Laryngoscope. https://doi.org/10.1002/lary.30806
Vancouver
Sanuki T, Takemoto N. Comparison of Botulinum Toxin Injections and Type 2 Thyroplasty for Adductor Spasmodic Dysphonia. The Laryngoscope. 2023. doi:10.1002/lary.30806
BibTeX
@article{Sanuki2023,
author = {Sanuki, Tetsuji and Takemoto, Naoki},
title = {Comparison of Botulinum Toxin Injections and Type 2 Thyroplasty for Adductor Spasmodic Dysphonia},
journal = {The Laryngoscope},
year = {2023},
doi = {10.1002/lary.30806}
}
EUVIMED